Schizophrenic PsychosesPhase 2NACPSYNCT01354132
N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
A Phase 2 study testing n-acetylcysteine in people with Schizophrenic Psychoses, run by Beth Israel Deaconess Medical Center at 2 sites in United States.
Trial summary
The investigators seek to examine the effect of add-on N-Acetyl-Cysteine (NAC) in the early phase of schizophrenia spectrum illness in collaboration with researchers Kim Do, PhD, and Philippe Conus, MD in Switzerland. Read more about this study
- Who is it for?
- Ages 18 to 35 years
- Conditions the study is for
- Schizophrenic Psychoses
- What is being tested?
- n-acetylcysteine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 2 sitesUnited States
- Study dates
- May 2011to Aug 2014
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Capacity to provide informed consent
- DSM IV TR diagnosis of schizophrenia, schizophreniform, schizoaffective
- Psychiatric and medical stability
- Prescribing clinician's premission to participate, assurance of medical stability
- Having met threshold criteria for psychosis on CAARMS (Comprehensive Assessment of at Risk Mental States Scale) Psychosis subscale
- Up to 12 months of antipsychotic treatment
Who cannot join
- Severe medical comorbidities
- Previous cerebral trauma
- Substance induced psychosis or organic psychosis
- Mental retardation
- NAC allergy
- Pregnancy, females and males planning pregnancy
- Treatment with antioxidants
- Insufficient command of English
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Massachusetts Mental Health Center
Boston, Massachusetts, 02215
About this study
Official title: Effects of Oral N-Acetyl-Cysteine (NAC) in the Early Phase of Schizophrenia Spectrum Psychosis: Randomized, Parallel, Double- Blind, Placebo Controlled Trial
The investigators seek to examine the effect of add-on N-Acetyl-Cysteine (NAC) in the early phase of schizophrenia spectrum illness in collaboration with researchers Kim Do, PhD, and Philippe Conus, MD in Switzerland. Modifications of brain structure are thought to occur during the pre-illness phase and around the transition to psychosis. Therefore, studying new treatments that could target changes occurring during this period is of critical importance.
Aims:
Does add-on NAC treatment in early psychosis influence:
- positive and negative symptoms
- extrapyramidal side-effects of other medication
- plasma concentration of glutathione
- Mismatch Negativity, a physiological marker
Read the detailed description
The study proposes that a glutathione deficit leading to an abnormal response to oxidative stress is a vulnerability factor, combined with other brain specific factors, in brain functioning of some individuals with schizophrenia (Do et al., 2010). N-acetyl-cysteine is hypothesized to cross the blood-brain barrier and increase glutathione in the brain.
- Conditions
- Schizophrenic Psychoses
- Being tested
- n-acetylcysteine, Placebo
- Keywords
- schizophrenia, schizoaffective, schizophreniform, early schizophrenia spectrum psychosis
- Medical subject headings
- Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
n-acetylcysteineDrug
Also called PharmaNAC
900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
PlaceboDrug
Placebo tablets are placed in water or juice in the AM and PM
| Study group | Role | What they receive |
|---|---|---|
| n-acetyl-cysteine | Active comparator | N-Acetyl cysteine effervescent tablets in water 2 in am and 1 in pm for 28 weeks Receives: Drug: n-acetylcysteine |
| Placebo | Placebo comparator | matching effervescent tablets in water 2 in am and 1 in pm Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Negative Symptoms of Schizophrenia as Measured on the PANSS
Positive and Negative Symptom Scale was used to assess psychopathology. The sum of items N1 - N7 including N1) blunted affect, N2) emotional withdrawal, N3) poor rapport, N4) passive apathetic social withdrawal, N5) difficulty in abstract thinking, N6) lack of spontaneity and flow of conversation, and N7) sterotyped thinking were used to analyze negative symptoms of schizophrenia and were assessed for the previous week:
RATING SCALE
1: Absent 2: Minimal 3: Mild 4: Moderate 5: Moderate Severe 6: Severe 7: Extreme The higher the score the worse the symptoms. The lowest possible score is 7 and the highest possible score is 49 .
Measured: at 6 months
Secondary outcomes (20)
Change in Positive Symptoms (PANSS)
Positive and Negative Symptom Scale was used to assess psychopathology. The Positive symptom subscale of schizophrenia includes the sum of items P1 -P7 including P1) Delusions, P2) conceptual Disorganization, P3) Hallunicatory Behavior, P4) Excitement, P5) Grandiosity, P6) Suspiciousness and Persecution, and P7) Hostility and were assessed for the previous week:
RATING SCALE
1: Absent 2: Minimal 3: Mild 4: Moderate 5: Moderate Severe 6: Severe 7: Extreme The higher the score the worse the symptoms. The lowest possible score is 7 and the highest possible score is 49 .
Measured: at 6 months
Global Assessment of Functioning (GAF)
Measure Description: Clinical Measure of Global level of Symptoms (Sx) and Functioning from 1 (Worst) to 100 (Best) in groups of 10:
100 - 91: Superior functioning 90 - 81: Absent or minimal Sx 80 - 71: If symptoms are present and expected 70 - 61:Some mild Sx 60 - 51: Moderate Sx 50 - 41: Serious Sx 40 - 31: Some impairment in reality testing or communication 30 - 21: Behavior is considerably influenced by delusions or hallucinations 20 - 11: Some danger of hurting self or others 10 - 1: Persistent danger of severely hurting self or others
Measured: at 6 months
Social and Occupational Functioning Assessment Scale (SOFAS)
Measure of social and occupational functioning using the Social and Occupational Functioning Assessment Scale Measure Description: Rating of Overall Social and Occupational Functioning on a scale of 1 (worst) to 100 (best) in groups of 10:
100-91: Superior functioning 90-81: Good functioning 80-71: Slight impairment 70-61: Some difficulty 60-51: Moderate difficulty 50-41: Serious impairment 40-31: Major impairment 30-21: Inability to function in almost all areas 20-11: Unable to function independently 10-1: Unable to function without harming self or others
Measured: at 6 months
Change in Cognition and Working Memory (MATRICS) Speed of Processing
The MATRICS is neurocognitive battery designed to assess cognition. Processing speed is a composite score including the following tests: Trail Making Test, BACS: Symbol Coding, Category Fluency: Animal Naming. The score is a standardized T-Score which indicates the number of standard deviations above or below the mean, a T-Score of 50, in 10 point increments. A T-Score of 60 indicates 1 standard deviation above the mean and a T-Score of 40 indicates 1 standard deviation below the mean. A score below 50 indicated cognitive processing below that of an age and gender matched healthy control population. A score above 50 indicates cognitive processing above that of an age and gender matched healthy control population.
Measured: at 6 months
Change in Cognition and Working Memory (MATRICS) Working Memory
The MATRICS is neurocognitive battery designed to assess cognition. Working Memory score is a composite score based on the following sub-test WMS-III Spatial Span and Letter-Number Span. The score is a standardized T-Score which indicates the number of standard deviations above or below the mean, a T-Score of 50, in 10 point increments. A T-Score of 60 indicates 1 standard deviation above the mean and a T-Score of 40 indicates 1 standard deviation below the mean. A score below 50 indicated cognitive processing below that of an age and gender matched healthy control population. A score above 50 indicates cognitive processing above that of an age and gender matched healthy control population.
Measured: at 6 months
Change in Cognition and Working Memory (MATRICS) Attention and Vigilance
The MATRICS is neurocognitive battery designed to assess cognition. Sustained attention and Vigilance is a composite score based on the Continuous Performance Test -Identical Pairs. The score is a standardized T-Score which indicates the number of standard deviations above or below the mean, a T-Score of 50, in 10 point increments. A T-Score of 60 indicates 1 standard deviation above the mean and a T-Score of 40 indicates 1 standard deviation below the mean. A score below 50 indicated cognitive processing below that of an age and gender matched healthy control population. A score above 50 indicates cognitive processing above that of an age and gender matched healthy control population.
Measured: at 6 months
Change in Cognition and Working Memory (MATRICS) Verbal Learning
The MATRICS is neurocognitive battery designed to assess cognition. Verbal Learning is a composite score based on the Hopkins Verbal Learning Test-Revised: Immediate Recall. The score is a standardized T-Score which indicates the number of standard deviations above or below the mean, a T-Score of 50, in 10 point increments. A T-Score of 60 indicates 1 standard deviation above the mean and a T-Score of 40 indicates 1 standard deviation below the mean. A score below 50 indicated cognitive processing below that of an age and gender matched healthy control population. A score above 50 indicates cognitive processing above that of an age and gender matched healthy control population.
Measured: at 6 months
Change in Cognition and Working Memory (MATRICS) Visual Learning
The MATRICS is neurocognitive battery designed to assess cognition. Visual Learning is a composite score based on the Brief Visuospatial Memory test - Revised: Immediate Recall. The score is a standardized T-Score which indicates the number of standard deviations above or below the mean, a T-Score of 50, in 10 point increments. A T-Score of 60 indicates 1 standard deviation above the mean and a T-Score of 40 indicates 1 standard deviation below the mean. A score below 50 indicated cognitive processing below that of an age and gender matched healthy control population. A score above 50 indicates cognitive processing above that of an age and gender matched healthy control population.
Measured: at 6 months
Change in Cognition and Working Memory (MATRICS) Reasoning and Problem Solving
The MATRICS is neurocognitive battery designed to assess cognition. Problem Solving is a composite score based on the NAB Mazes. The score is a standardized T-Score which indicates the number of standard deviations above or below the mean, a T-Score of 50, in 10 point increments. A T-Score of 60 indicates 1 standard deviation above the mean and a T-Score of 40 indicates 1 standard deviation below the mean. A score below 50 indicated cognitive processing below that of an age and gender matched healthy control population. A score above 50 indicates cognitive processing above that of an age and gender matched healthy control population.
Measured: at 6 months
Change in Blood Level of Glutathione
Glutathione is a tripeptide comprised of three amino acids (cysteine, glutamic acid, and glycine) and acts as an antioxidant, a free radical scavanger and a detoxifying agent. Glutathione is an important co-factor for the enzyme glutathione peroxidase used in the uptake of amino acids. The level of glutathione is measured in blood cells.
Measured: at 6 months
Blood Plasma Level of Cysteine
Cysteine is an amino acid, a building block for proteins and is used throughout the body and was measured in blood plasma.
Measured: at 6 months
GPxbc Glutathione Peroxidase Activity in Blood Cells
GPxBC is a measurement of glutathiione peroxidase enzymatic activity in glutathione synthesis and the redox system in blood cells. Measured as umol/min/gHb from blood cells.
Measured: at 6 months
Glutamine Brain Level for NAC Group
Glutamine is measured in the medial prefrontal cortex using Magnetic Resonance Spectroscopy (H-MRS) and is a chemical that works to protect the brain from high levels of excitatory chemicals such as glutamate.
Measured: at 6 months
Glutamine Brain Level for Placebo Group
Glutamine is measured in the medial prefrontal cortex using Magnetic Resonance Spectroscopy (H-MRS) and is a chemical that works to protect the brain from high levels of excitatory chemicals such as glutamate.
Measured: at 6 months
Glutamate Brain Level for NAC Group
Brain marker, glutamate, was measured using Magnetic Resonance Spectroscopy (H-MRS) in the medial prefrontal cortex. Glutamate is an excitatory neurotransmitter in the brain.
Measured: at 6 months
Glutamate Brain Level for Placebo Group
Glutamine is measured in the medial prefrontal cortex using Magnetic Resonance Spectroscopy (H-MRS) and is a chemical that works to protect the brain from high levels of excitatory chemicals such as glutamate.
Measured: at 6 months
Glutathione Brain Level for NAC Group
measured by H-MRS in the medial prefrontal cortex Brain markers, glutathione was measured using Magnetic Resonance Spectroscopy (H-MRS) in the medial prefrontal cortex. Glutathione is a tripeptide comprised of three amino acids (cysteine, glutamic acid, and glycine) and acts as an antioxidant, a free radical scavanger and a detoxifying agent. Glutathione is an important co-factor for the enzyme glutathione peroxidase used in the uptake of amino acids.
Measured: at 6 months
Glutathione Brain Level for Placebo Group
measured by H-MRS in the medial prefrontal cortex Brain markers, glutathione was measured using Magnetic Resonance Spectroscopy (H-MRS) in the medial prefrontal cortex. Glutathione is a tripeptide comprised of three amino acids (cysteine, glutamic acid, and glycine) and acts as an antioxidant, a free radical scavanger and a detoxifying agent. Glutathione is an important co-factor for the enzyme glutathione peroxidase used in the uptake of amino acids.
Measured: at 6 months
Myo-Inositol Brain Level for the NAC Group
Myo-Inositol is measured in the medial prefrontal cortex using Magnetic Resonance Spectroscopy (H-MRS)MRS and is a chemical that works to protect the brain from high levels of excitatory chemicals such as glutamate.
Measured: at 6 months
Myo-Inositol Brain Level for Placebo Group
Myo-Inositol is measured in the medial prefrontal cortex using Magnetic Resonance Spectroscopy (H-MRS)MRS and is a chemical that works to protect the brain from high levels of excitatory chemicals such as glutamate.
Measured: at 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2011 (estimated)
- Study startMay 2011
- Primary completionAug 2014
- Study completionAug 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Schizophrenic PsychosesStudies of the same condition, open and under way.
- More trials run by Beth Israel Deaconess Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Center de Neurosciences Psychiatrique, Lausanne, Switzerland
- Responsible party
- Principal investigator, Larry Seidman, Beth Israel Deaconess Medical Center
- Investigators
- Ann Cousins, PhD, APRN, Study director, Beth Israel Deaconess Medical CenterT. U. Wilson Woo, MD, PhD, Study chair, Harvard Medical School (HMS and HSDM)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01354132
- Sponsor's protocol ID
- 2008P000460
- Other IDs
- 107865
- Acronym
- NACPSY
- Status last verified
- Jun 2017
- First submitted
- 13 May 2011
- Last updated
- 5 Jul 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Do KQ, Conus P, Cuenod M. Redox dysregulation and oxidative stress in schizophrenia: nutrigenetics as a challenge in psychiatric disease prevention. World Rev Nutr Diet. 2010;101:131-153. doi: 10.1159/000314518. Epub 2010 Apr 30. No abstract available.
PubMed 20436260
Study at a glance
From the registry record, last updated by the sponsor on 5 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Oral N-Acetyl-Cysteine (NAC) in the Early Phase of Schizophrenia Spectrum Psychosis: Randomized, Parallel, Double- Blind, Placebo Controlled Trial
- ClinicalTrials.gov ID
- NCT01354132
- Acronym / sponsor ID
- NACPSY / 2008P000460
- Conditions
- Schizophrenic Psychoses
- Keywords
- schizophrenia, schizoaffective, schizophreniform, early schizophrenia spectrum psychosis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Beth Israel Deaconess Medical CenterUniversity, hospital or other
- Collaborators
- Center de Neurosciences Psychiatrique, Lausanne, Switzerland
- Study start
- May 2011
- Primary completion
- Aug 2014 (actual)
- Study completion
- Aug 2014 (actual)
- First posted
- 16 May 2011 (estimated)
- Results
- Posted 7 Jun 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators seek to examine the effect of add-on N-Acetyl-Cysteine (NAC) in the early phase of schizophrenia spectrum illness in collaboration with researchers Kim Do, PhD, and Philippe Conus, MD in Switzerland. Modifications of brain structure are thought to occur during the pre-illness phase and around the transition to psychosis. Therefore, studying new treatments that could target changes occurring during this period is of critical importance.
Aims:
Does add-on NAC treatment in early psychosis influence:
- positive and negative symptoms
- extrapyramidal side-effects of other medication
- plasma concentration of glutathione
- Mismatch Negativity, a physiological marker
Detailed description
The study proposes that a glutathione deficit leading to an abnormal response to oxidative stress is a vulnerability factor, combined with other brain specific factors, in brain functioning of some individuals with schizophrenia (Do et al., 2010). N-acetyl-cysteine is hypothesized to cross the blood-brain barrier and increase glutathione in the brain.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| n-acetyl-cysteine | Active comparator | Drug: n-acetylcysteineN-Acetyl cysteine effervescent tablets in water 2 in am and 1 in pm for 28 weeks |
| Placebo | Placebo comparator | Drug: Placebomatching effervescent tablets in water 2 in am and 1 in pm |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Capacity to provide informed consent
- DSM IV TR diagnosis of schizophrenia, schizophreniform, schizoaffective
- Psychiatric and medical stability
- Prescribing clinician's premission to participate, assurance of medical stability
- Having met threshold criteria for psychosis on CAARMS (Comprehensive Assessment of at Risk Mental States Scale) Psychosis subscale
Key exclusion criteria (8 listed)
- Severe medical comorbidities
- Previous cerebral trauma
- Substance induced psychosis or organic psychosis
- Mental retardation
- NAC allergy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| n-acetylcysteineAlso: PharmaNAC900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM | Drug | n-acetyl-cysteine |
| PlaceboPlacebo tablets are placed in water or juice in the AM and PM | Drug | Placebo |
Primary outcome
Change in Negative Symptoms of Schizophrenia as Measured on the PANSS
Time frame: at 6 months
Positive and Negative Symptom Scale was used to assess psychopathology. The sum of items N1 - N7 including N1) blunted affect, N2) emotional withdrawal, N3) poor rapport, N4) passive apathetic social withdrawal, N5) difficulty in abstract thinking, N6) lack of spontaneity and flow of conversation, and N7) sterotyped thinking were used to analyze negative symptoms of schizophrenia and were assessed for the previous week: RATING SCALE 1: Absent 2: Minimal 3: Mild 4: Moderate 5: Moderate Severe 6: Severe 7: Extreme The higher the score the worse the symptoms. The lowest possible score is 7 and the highest possible score is 49 .
20 secondary outcomes
Change in Positive Symptoms (PANSS)
Time frame: at 6 months
Global Assessment of Functioning (GAF)
Time frame: at 6 months
Social and Occupational Functioning Assessment Scale (SOFAS)
Time frame: at 6 months
Change in Cognition and Working Memory (MATRICS) Speed of Processing
Time frame: at 6 months
Change in Cognition and Working Memory (MATRICS) Working Memory
Time frame: at 6 months
Change in Cognition and Working Memory (MATRICS) Attention and Vigilance
Time frame: at 6 months
Change in Cognition and Working Memory (MATRICS) Verbal Learning
Time frame: at 6 months
Change in Cognition and Working Memory (MATRICS) Visual Learning
Time frame: at 6 months
Change in Cognition and Working Memory (MATRICS) Reasoning and Problem Solving
Time frame: at 6 months
Change in Blood Level of Glutathione
Time frame: at 6 months
Blood Plasma Level of Cysteine
Time frame: at 6 months
GPxbc Glutathione Peroxidase Activity in Blood Cells
Time frame: at 6 months
Glutamine Brain Level for NAC Group
Time frame: at 6 months
Glutamine Brain Level for Placebo Group
Time frame: at 6 months
Glutamate Brain Level for NAC Group
Time frame: at 6 months
Glutamate Brain Level for Placebo Group
Time frame: at 6 months
Glutathione Brain Level for NAC Group
Time frame: at 6 months
Glutathione Brain Level for Placebo Group
Time frame: at 6 months
Myo-Inositol Brain Level for the NAC Group
Time frame: at 6 months
Myo-Inositol Brain Level for Placebo Group
Time frame: at 6 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jul 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 20436260Do KQ, Conus P, Cuenod M. Redox dysregulation and oxidative stress in schizophrenia: nutrigenetics as a challenge in psychiatric disease prevention. World Rev Nutr Diet. 2010;101:131-153. doi: 10.1159/000314518. Epub 2010 Apr 30. No abstract available.
Related trials for Schizophrenic Psychoses
RecruitingPhase 1
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Schizophrenia, Schizo-Affective Disorder
Recruiting
Seven-step Phenomenological Psychotherapy for Self-disorder - a Pilot Study
Psychosis;Schizophrenic
Recruiting
Study of Electrophysiological Markers Related to the Cognitive and Affective Processes Behind Empathic Behaviour in Schizophrenic Spectrum Disorder
Schizophrenia
Active, not recruiting
Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial
Schizophrenia Disorders, Psychotic Disorder
Not yet recruitingObservational study
Functional Magnetic Resonance Imaging Study in Schizophrenia Patients and Correlation With Cognitive Impairments
Schizophrenia, Cognitive Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ann Cousins, PhD, APRN study director
Beth Israel Deaconess Medical Center
T. U. Wilson Woo, MD, PhD study chair
Harvard Medical School (HMS and HSDM)
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing n-acetylcysteine in people with Schizophrenic Psychoses, run by Beth Israel Deaconess Medical Center at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 Jun 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Negative Symptoms of Schizophrenia as Measured on the PANSS (time frame: at 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01354132, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jul 2017.